Use of Propranolol Hydrochloride in the Treatment of Metastatic STS
Status:
Unknown status
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
Fifty patients with pathological proof of malignant soft tissue sarcoma will receive
Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.
- The primary end point : To assess Progression Free Survival (PFS)
- The secondary end points : To assess Overall Survival (OS) and Toxicity Profile